Danske Bank A S Invests $6.41 Million in Lantheus Holdings, Inc. $LNTH

Danske Bank A S bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 57,791 shares of the medical equipment provider’s stock, valued at approximately $6,411,000.

Several other institutional investors also recently bought and sold shares of LNTH. Farallon Capital Management LLC grew its stake in shares of Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares during the period. Norges Bank acquired a new position in shares of Lantheus in the 4th quarter valued at $76,197,000. Freestone Grove Partners LP boosted its holdings in Lantheus by 4,114.8% during the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock worth $40,497,000 after buying an additional 594,088 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Lantheus by 440.3% during the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after buying an additional 582,661 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in Lantheus by 686.1% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock valued at $45,423,000 after buying an additional 522,678 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Performance

NASDAQ:LNTH opened at $99.97 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The company has a fifty day moving average of $104.08 and a two-hundred day moving average of $90.35. The stock has a market capitalization of $6.53 billion, a PE ratio of 24.15 and a beta of -0.03. Lantheus Holdings, Inc. has a fifty-two week low of $49.67 and a fifty-two week high of $111.86.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the firm posted $1.57 earnings per share. The company’s revenue was up 2.7% compared to the same quarter last year. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research note on Thursday, May 7th. Truist Financial cut Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. Leerink Partners set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. Finally, TD Cowen cut Lantheus from a “buy” rating to a “hold” rating and reduced their price target for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.